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OBJECTIVES:TheNational List of Health Services (NLHS) in Israel has been updated
annually since 1999 but results from economic evaluations (EE) were not used to
support coverage decisions. We explored the potential availability of EE results to
the committee responsible for updating the NLHS at the times of coverage deci-
sions and whether availability and use of these data could have altered these
decisions. METHODS: We used the Tufts Medical Center Cost-Effectiveness Anal-
ysis Registry (http://www.cearegistry.org) to search for relevant cost/QALY EE for
all drugs and their relevant indications added to the NLHS from 1999 through 2008.
For each pair of drug and cost/QALY publication we recorded the publication date,
the intervention(s) and comparator(s) considered and the incremental cost-effec-
tiveness ratio (ICER) to determine value for money. Based on available ICERs we
qualitatively classified each coverage decision into one of three categories: 1)The
coverage decision can be justified on EE grounds (EE suggest the drug is either
dominant/cost-saving or provides good value for money); 2)The coverage decision
cannot be justified on EE grounds; 3)The evidence from EE is mixed and we could
not determine whether the coverage decision can be justified or not. RESULTS:
Relevant cost/QALY analyses were found for 181(40%) of 451 drugs included in the
updates of the NLHS of which only 71 (16%) of drugs had relevant EE prior to the
coverage decision. Based on the evidence gathered from EE prior to and following
the coverage decision, we suggest that decisions were correct in 56% of the cases,
incorrect in 17% and ambiguous in 27%. CONCLUSIONS: The use of EE to support
coverage decisions could have altered decisions in a sizable proportion of drugs
added to the NLHS in Israel. Avoiding the use of results from EE to support public
funding of drugs may lead to a non-optimal use of scarce healthcare resources.
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OBJECTIVES: Orphan drug (OD) legislation has been highly successful in incentiv-
ising pharmaceutical companies to invest in developing medicines for previously-
ignored rare diseases. Since 2005, a third of all new drug approvals in the US have
been ODs, and worldwide the market is forecast to grow at a CAGR of 6%, reaching
$112bn in 2014. Although these products still only account for 2-3% of total drug
budgets in the US and EU, their burgeoning number is placing increased pressure
on funding. This poster aims to explore how payers in the US and EU are respond-
ing to these financial demands. METHODS: We reviewed all ODs approved in the
US and EU since 1st January 2000 and, for each, calculated the average cost per
patient per year, based on public prices in the US and 5EU. We also reviewed
published payer assessments of these products, and all government proposals
regarding OD policies since 2005. RESULTS: Since 2007, there has been an obvious
drop in prices secured for novel ODs. In the EU alone, the average cost per patient
per year for products approved in 2008 to 2010 (€34,890) is 73% lower than for those
approved in 2000 to 2007 (€129,228). Furthermore, our analysis suggests payers are
adopting a more discerning approach to the way they evaluate orphan drugs, es-
pecially those perceived to be exploiting the original intent of the legislation. For
example, Germany’s recent healthcare reforms highlighted plans to target ODs
that fail to demonstrate meaningful patient benefits, such as survival, and all ODs
exceeding annual sales of €50m will have to submit a cost-benefit analysis.
CONCLUSIONS: Payers are clamping down on “opportunistic” ODs and only those
with a robust body of evidence supporting both the clinical and economic argu-
ments for their use will secure favourable pricing and market access.
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OBJECTIVES: HTA agencies worldwide have varying processes that allow consul-
tation with stakeholders during decision-making. The objective of this study is to
determine the impact of the National Institute for Health and Clinical Excellence
(NICE) Single Technology Appraisal (STA) consultation stage on reimbursement
decisions of pharmaceuticals. METHODS: Documentation was accessed from the
NICE website for all STA’s conducted between 2006 and August 2010. Details of the
first Appraisal Consultation Document (ACD) draft decision, subsequent ACDs,
Final Appraisal Determination (FAD) and final guidance decision were extracted.
The decisions were categorised with respect to the licensed indication (recom-
mended, restricted, not recommended, only in research). Details of the further
analysis and evidence submitted by the manufacturer as a result of consultation
were extracted. These data were analysed for the different stages of
decision-making. RESULTS: The website search identified 55 NICE appraisals of
which over fifty percent were for cancer medicines. Final decisions (draft first
provisional decision) included 36% (13%) recommended, 36% (20%) restricted deci-
sion, 16% (56%) not recommendeddecision and 11% (11%) terminated decision. One
appraisal contained only in research recommendations in addition for use in rou-
tine practice. An ACDwas produced in 42 appraisals, followed by themanufacturer
providing further economic analysis in 26 appraisals, a patient access scheme in 5
appraisals and new clinical evidence in 2 appraisals. Types of further economic
analysis provided by the manufacturer were for other treatments/strategies; dif-
ferent modelling assumptions; alternative survival distributions; further sensitiv-
ity analysis; and other. CONCLUSIONS: NICE’s iterative consultation process al-
lows consideration of evidence and wide consultation with stakeholders. This
results in evidence that is more appropriate for the evaluation of pharmaceutical’s
and partly explains the higher recommendation rate when compared with similar
international reimbursement agencies. There is a need for further research to un-
derstand the impact of the different processes employed across countries’ deci-
sion-making.
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OBJECTIVES: Comparative effectiveness (US) and value-based pricing (VBP) (UK)
are anticipated to bring changes froma ‘free-pricing’ system for drugs to onewhere
prices are influenced by governmental authorities. A product’s value will take into
account additional factors, such as wider societal benefits and therapeutic innova-
tion. The aim of this research is to determine the impact of comparative effective-
ness and VBP on the price and market access of new drugs in depression.
METHODS:A literature reviewwas conducted using electronic databases (Medline,
Embase, Google Scholar). The search was performed for the years 2009-2011 and
key terms included comparative effectiveness USA, value based pricing UK, drug
value and societal benefits. In addition, an analysis of a UK Department of Health
consultation paper and the US Agency for Healthcare Research and Quality policy
documents was performed in order to determine how comparative effectiveness
and VBP may affect the market access and commercial viability of products in
disease area of depression (SSRIs, SNRIs and atypical antidepressants). A spread-
sheet was used to capture data and a comparison was undertaken to compare and
contrast the twomarkets and the different implications. RESULTS: The addition of
comparative effectiveness and VBP are to take account of indirect costs associated
with all disease areas. Depression has high indirect associated costs associated
and, as such, the value of novel antidepressants will increase. This is likely to
enable better access to new products. CONCLUSIONS: The move to comparative
effectiveness and VBP is likely to change the market access of products, particu-
larly in certain disease areas. There will be more positive drivers for investment in
the disease area of depression. Moreover, decisions taken at themargin during the
drug development processwill be impacted as any change inmarket access is likely
to affect the ‘Go/No go’ decision criteria.
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OBJECTIVES: Many factors influence pharmaceutical reimbursement decisions.
This study aims to determine the influence of factors considered in the evaluation
of pharmaceuticals on the reimbursement decisions of government funded bodies
in OECD countries. METHODS: A search of MEDLINE, EMBASE, EconLit, Health Man-
agement Information Consortium, NHS EED and REPEC Economic working papers until
July 2010 was conducted. A hand search of the International Journal of Technology
Assessment in Health Care was undertaken (1990-2010). The following study de-
signs were eligible: experimental, quasi-experimental, retrospective, prospective,
case series and surveys or questionnaires design. The influential factors were re-
viewed across and within OECD countries. RESULTS: The search identified 12
quantitative studies and 23 qualitative studies. The quantitative studies consid-
ered the correlation between factors and decisions either through regression anal-
ysis of retrospective decisions or discrete choice experiments. Cost-effectiveness
was found to be consistently influential for reimbursement decision-making in
Australia, England, Canada and The Netherlands. There was variation in the defi-
nition of clinical considerations and other factors in studies conducted in coun-
tries. This limited comparability within and across countries. Studies reported
mixed evidence of the influence of the quality, quantity and type of clinical evi-
dence, robustness of economic models, sensitivity analysis, budget impact, lack of
alternative therapy and severity of disease on reimbursement decisions. Qualita-
tive studies reported narrative descriptions, case studies and interviews with de-
cision-makers. These studies supported the influence of cost-effectiveness found
in the quantitative evidence. They additionally described the influence of the com-
position of the decision panel, committee deliberations, stakeholder involvement
and lobbying on decisions. CONCLUSIONS: There is limited evidence on the influ-
ence of evaluation factors on reimbursement decisions in a few OECD countries
with established reimbursement processes. Wider investigation of the factors in-
fluential in other countries would allow comparison of the similarities and differ-
ences across OECD countries.
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OBJECTIVES: In this paper we estimate the relationship between the financial im-
pact of a new drug on the health care system in Australia and the probability of the
drug being recommended for reimbursement by the Pharmaceutical Benefits Ad-
visory Committee (PBAC).METHODS: Data in the PBAC summary database regard-
ing drug-reimbursement decisions made between July 2005 and November 2009
were abstracted. Financial impact was categorized as A$0 or less, greater than A$0
up through A$10 million, and greater than A$10 million per year. Descriptive anal-
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